2097002-61-2 Usage
Uses
Used in Oncology:
LOXO-195 is used as a targeted cancer therapy for its ability to inhibit the TRK family of proteins, which are involved in the growth and spread of cancer cells. This application is particularly relevant for treating certain types of solid tumors and sarcomas, where the compound has shown promising results in early studies.
Used in Pharmaceutical Development:
In the pharmaceutical industry, LOXO-195 is utilized in the development of new cancer treatments. Its role as a TRK inhibitor positions it as a candidate for further research and clinical trials aimed at establishing its safety and effectiveness in treating cancer patients.
Used in Clinical Trials:
LOXO-195 is used in clinical trials to evaluate its safety, tolerability, and effectiveness as a cancer treatment. These trials are essential for determining the appropriate dosing, potential side effects, and overall therapeutic value of the compound in treating specific types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 2097002-61-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,0,9,7,0,0 and 2 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 2097002-61:
(9*2)+(8*0)+(7*9)+(6*7)+(5*0)+(4*0)+(3*2)+(2*6)+(1*1)=142
142 % 10 = 2
So 2097002-61-2 is a valid CAS Registry Number.
2097002-61-2Relevant articles and documents
FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
-
, (2019/05/15)
The present application in some embodiments provides a pharmaceutical composition comprising Compound (1), and a compounding agent. Further provided herein are methods of making and methods of using the pharmaceutical compositions, for example, in the treatment of cancer.
PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
-
, (2018/05/24)
In some embodiments, provided herein are processes for preparing a compound of Formula C or a salt thereof, as disclosed herein. In some embodiments, provided herein is a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof. In some embodiments, provided herein is a solid form of the compound, such as a crystalline form of the compound crystalline Form I.
